Current position

Stanley Druckenmiller’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Duquesne Family OfficeVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2012Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares1.77MHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Duquesne Family Office first reported Eli Lilly in Q2 2012. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Duquesne Family Office currently reports 12.38K shares. The latest verified filing showed: New position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
New position+12.38K shares · 12.38K shares reported
Filing context

Quarter-end price $1,199.43 · Estimated holding basis $1,199.43

Q3 2025
Sold the entire position−100.68K shares · No shares reported at quarter-end
Q2 2025
Bought 6.2% more+5.85K shares · 100.68K shares reported after the change
Filing context

Quarter-end price $779.53 · Estimated holding basis $789.92

Q1 2025
Bought 52.5% more+32.64K shares · 94.83K shares reported after the change
Filing context

Quarter-end price $825.91 · Estimated holding basis $790.56

Q4 2024
New position+62.19K shares · 62.19K shares reported
Filing context

Quarter-end price $772.01 · Estimated holding basis $772.01

Q2 2024
Sold the entire position−61.66K shares · No shares reported at quarter-end

1 unchanged quarter is collapsed by default.

Portfolio importance

How important is Eli Lilly in Duquesne Family Office’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.3%Q2 2026
Current rank#58of 86 reported positions
Peak portfolio weight13.4%Q4 2022
Best historical rank#2Q3 2022
At peak importanceQ4 2022
LLY
13.4%
Largest holding
14.9%
Cross-investor discovery

Who else owns Eli Lilly?

Also reported by 4 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
LLY0.6% of reported portfolio
Ray DalioBridgewater Associates, LP
LLY0.4% of reported portfolio
George SorosSoros Fund Management
LLY0.3% of reported portfolio
Explore Eli Lilly across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,115.702026-09-11

Market context only; not an investor transaction price.

Latest filing quarter-end price$1,199.43Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$1,199.43Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Eli Lilly stock page →

This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.